Avalon GloboCare Expands KetoAir Breathalyzer Availability to the UK Market.

Avalon GloboCare will launch the KetoAir breathalyzer device in the UK on September 1, 2025. The handheld device measures breath acetone concentration for ketogenic health management and is owned and manufactured by Qi Diagnostics Limited. Avalon GloboCare believes KetoAir is uniquely positioned to empower individuals in achieving their health and wellness goals.

Avalon GloboCare Corp. (NASDAQ: ALBT) has announced the launch of its KetoAir™ breathalyzer device in the United Kingdom, marking the company's first international market expansion for this product following its successful U.S. market introduction. The KetoAir™ device, which measures breath acetone concentration to track ketosis and fat metabolism, will be available for purchase starting September 1, 2025, through the dedicated website KetoAir.uk.

The KetoAir™ breathalyzer, manufactured by Qi Diagnostics Limited, utilizes nano-sensor technology and is compatible with both iOS and Android platforms. It is designed for individuals following ketogenic diets for weight management, athletic performance enhancement, or therapeutic purposes. The device provides real-time insights into fat metabolism and ketosis, making it a valuable tool for those pursuing ketogenic lifestyles.

The UK launch represents a strategic move for Avalon GloboCare, which aims to capitalize on the growing adoption of ketogenic and low-carb diets in the UK. The company believes that the KetoAir™ device is uniquely positioned to empower individuals in achieving their health and wellness goals. The device is expected to be a companion to mobile applications, enhancing accessibility and convenience for users.

However, several factors may temper the immediate impact of this expansion. The announcement does not include details on distribution partnerships, retail placement, or projected revenue figures. Additionally, Avalon GloboCare does not manufacture the device itself; it is produced by Qi Diagnostics Limited, suggesting that Avalon operates primarily as a distributor or marketing partner. The direct-to-consumer online sales model indicates a focused but potentially limited distribution strategy, which allows Avalon to test market acceptance with minimal infrastructure investment while maintaining higher margins.

The ketogenic monitoring device market faces competition from established players and alternative testing methods like blood and urine testing. Without disclosed pricing or comparative advantage details, it is difficult to assess KetoAir's competitive positioning in this specialized health tech segment. Nonetheless, Avalon GloboCare's expansion into the UK market broadens its geographic footprint and represents a modest step in international growth.

References:
[1] https://www.stocktitan.net/news/ALBT/avalon-globo-care-to-launch-online-sales-of-keto-air-breathalyzer-in-c3ytj1e0q2j0.html